Tesaro price target lowered to $83 from $122 at Oppenheimer. Oppenheimer analyst Leah Rush Cann lowered her price target for Tesaro to $83 from $122 saying that she believes the current status of the PARP inhibitor market is resulting in less predictable physician adoption than is typical in oncology settings. The analyst is adjusting her 2018-2022 outlook for Tesaro to account for lower estimated Zejula sales.Cann reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.